Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of “Moderate Buy” by Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned a consensus rating of “Moderate Buy” from the seventeen research firms that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $55.06.

Several equities research analysts have weighed in on KYMR shares. UBS Group cut their price target on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Stephens restated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Truist Financial reaffirmed a “buy” rating and issued a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. BMO Capital Markets began coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 price target for the company. Finally, Guggenheim increased their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st.

Insider Activity

In related news, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now owns 54,826 shares in the company, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Kymera Therapeutics in the 4th quarter valued at approximately $55,000. Woodline Partners LP raised its position in Kymera Therapeutics by 2.3% in the fourth quarter. Woodline Partners LP now owns 537,428 shares of the company’s stock worth $21,621,000 after acquiring an additional 12,334 shares in the last quarter. Vident Advisory LLC acquired a new stake in Kymera Therapeutics in the fourth quarter valued at $236,000. State of Wyoming acquired a new stake in Kymera Therapeutics in the fourth quarter valued at $45,000. Finally, ProShare Advisors LLC grew its stake in shares of Kymera Therapeutics by 33.3% during the 4th quarter. ProShare Advisors LLC now owns 16,293 shares of the company’s stock worth $655,000 after purchasing an additional 4,071 shares during the period.

Kymera Therapeutics Trading Down 1.6 %

Kymera Therapeutics stock opened at $36.81 on Monday. The firm has a market capitalization of $2.38 billion, a P/E ratio of -15.73 and a beta of 2.18. Kymera Therapeutics has a twelve month low of $29.24 and a twelve month high of $53.27. The stock’s fifty day simple moving average is $39.77 and its 200-day simple moving average is $44.02.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.